MindWalk (NASDAQ:HYFT) Posts Earnings Results, Misses Expectations By $0.02 EPS

MindWalk (NASDAQ:HYFT) released its earnings results on Thursday. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.02), Zacks reports. The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $3.50 million. MindWalk had a negative net margin of 145.58% and a negative return on equity of 56.75%.

MindWalk Trading Down 7.3%

NASDAQ:HYFT traded down $0.10 during trading hours on Friday, hitting $1.22. 287,480 shares of the stock traded hands, compared to its average volume of 604,301. The firm has a market capitalization of $56.08 million, a price-to-earnings ratio of -2.02 and a beta of 0.58. The business’s 50 day simple moving average is $1.54. The company has a current ratio of 4.19, a quick ratio of 4.09 and a debt-to-equity ratio of 0.18. MindWalk has a fifty-two week low of $0.32 and a fifty-two week high of $3.25.

Institutional Investors Weigh In On MindWalk

Several hedge funds have recently bought and sold shares of the business. Virtu Financial LLC acquired a new stake in MindWalk during the 4th quarter worth about $51,000. Bridgeway Capital Management LLC purchased a new stake in shares of MindWalk in the fourth quarter worth approximately $91,000. Bank of Montreal Can lifted its position in shares of MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares in the last quarter. XTX Topco Ltd boosted its holdings in shares of MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares during the period. Finally, Jane Street Group LLC boosted its holdings in shares of MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares during the period. 6.70% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently commented on HYFT shares. Zacks Research upgraded MindWalk from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Weiss Ratings assumed coverage on MindWalk in a research report on Wednesday, January 14th. They set a “sell (d-)” rating on the stock. UBS Group reaffirmed a “buy” rating on shares of MindWalk in a report on Friday. Finally, HC Wainwright reissued a “buy” rating on shares of MindWalk in a research note on Friday. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, MindWalk currently has a consensus rating of “Hold”.

MindWalk Company Profile

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.